This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The global plasma derived therapy market is anticipated to reach US$58.26 billion in 2028, growing at a CAGR of 7.20% during the period spanning 2024-2028. The growth in the market has been driven by factors like rising geriatric population, increasing prevalence of genetic disorders, government initiatives, rising demand for albumin, escalating use of plasma proteins in pharmaceuticals, increasing usage of immunoglobulin, surging autoimmune disorders. The market is expected to face certain challenges such as high cost and stringent regulations. To overcome these challenges, the market would witness some key trends like technological advancements, rising demand for health insurance, escalating use of therapeutic protein drugs, and increasing adoption of plasma therapy in neurology.
The global plasma derived therapy market can be segmented as follows: Immunoglobulin, Hemophilia, Specialty, and Albumin. Immunoglobulin held a larger share of the market in 2023. Due to the rising use in primary immunodeficiency and neurological applications, the immunoglobulins market is predicted to grow. For example, Grifols, S.A., a pharmaceutical and chemical company, launched HyperHEP B, a new formulation of immune globulin derived from human plasma for hepatitis B postexposure prophylaxis, in June 2023, propelling the industry forward.
The global plasma derived therapy market by region can be segmented into the following: North America, Europe, Asia Pacific, and LAMEA. North America held a larger share of the market in 2023. Growing use of immunoglobulins in various therapeutic domains, increased plasma collection (and the number of plasma collection facilities), and rising prevalence of respiratory disorders and alpha-1-antitrypsin deficiency are all driving market expansion (AATD).
Scope of the report
- The report provides a comprehensive analysis of the global plasma derived therapy market, segmented into Immunoglobulin, Hemophilia, Specialty, and Albumin.
- The major regional markets North America, Europe, Asia Pacific, and LAMEA have been analyzed.
- The market dynamics such as growth drivers, market trends and challenges are analyzed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (ADMA Biologics, Kedrion, Grifols, Takeda Pharmaceutical Company, Octapharma, and CSL Limited) are also presented in detail.
Key Target Audience
- Plasma collection Centers
- End Users (Hospital, Medical centers, Clinical Institutes)
- Healthcare Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities
Please note: 10% free customization equates to up to 3 hours of analyst time.
Table of Contents
Companies Mentioned
- CSL Limited
- Grifols
- Takeda Pharmaceutical Company
- Octapharma AG
- Kedrion
- ADMA Biologics
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 76 |
| Published | June 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 44.12 Billion |
| Forecasted Market Value ( USD | $ 58.26 Billion |
| Compound Annual Growth Rate | 7.2% |
| Regions Covered | Global |
| No. of Companies Mentioned | 6 |
